Trastuzumab emtansine improves outcomes in HER2-positive breast cancer
Researchers report that adjuvant (post-surgical) trastuzumab emtansine (T-DM1) treatment of women with high-risk HER2-positive breast cancer has reduced their long-term risk of death or invasive disease by 46%… read more.